title: The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.
abstract: Using a reduced-intensity stem cell transplantation (RIST) schedule, 24 patients with Philadelphia (Ph1) (+) chronic myelogenous leukemia (CML) in first chronic phase (CP) were prospectively allografted in four Latin American countries: México, Brazil, Colombia and Venezuela, using HLA-identical siblings as donors. The median age of the patients was 41 years (range 10-71 years); there were eight females. Patients received a median of 4.4 x 10(6)/kg CD34 cells. The median time to achieve above 0.5 x 10(9)/l granulocytes was 12 days, range 0-41 days, and the median time to achieve above 20 x 10(9)/l platelets was also 12 days, range 0-45 days. In all, 22 patients are alive 81-830 (median 497) days after RIST. The 830-day probability of survival is 92%, and the median survival has not been reached, being beyond 830 days. A total of 11 patients (46%) developed acute graft-versus-host disease (GVHD), and seven of 23 (30%) developed chronic GVHD. Two patients died 43 and 210 days after RIST, one as a result of sepsis and the other of chronic GVHD. The 100-day mortality was 4.4%, and transplant-related mortality was 8%. RIST for patients with CML in CP appears to be an adequate therapeutic option.
authors.affiliation: Centro de Hematología y Medicina Interna de Puebla, Puebla, México. gruiz1@clinicaruiz.com
authors.forename: G J
authors.initials: GJ
authors.lastname: Ruiz-Argüelles
authors.forename: D
authors.initials: D
authors.lastname: Gómez-Almaguer
authors.forename: A
authors.initials: A
authors.lastname: Morales-Toquero
authors.forename: C H
authors.initials: CH
authors.lastname: Gutiérrez-Aguirre
authors.forename: J
authors.initials: J
authors.lastname: Vela-Ojeda
authors.forename: M A
authors.initials: MA
authors.lastname: García-Ruiz-Esparza
authors.forename: C
authors.initials: C
authors.lastname: Manzano
authors.forename: A
authors.initials: A
authors.lastname: Karduss
authors.forename: A
authors.initials: A
authors.lastname: Sumoza
authors.forename: C
authors.initials: C
authors.lastname: de-Souza
authors.forename: E
authors.initials: E
authors.lastname: Miranda
authors.forename: S
authors.initials: S
authors.lastname: Giralt
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001781:Blood Component Removal; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate